Eli Lilly and Co. has named Kimberly Blackwell vice president of early phase development and immuno-oncology. She will join Lilly Oncology March 12. Blackwell is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center. She also serves as co-director of the Duke women’s cancer program, associate director for strategic relations for the Duke Cancer Institute, research scholar for Susan G. Komen and senior strategist for the Duke Innovation and Entrepreneurship Program.
Blackwell is a graduate of Mayo Clinic Medical School. She has played a major role in developing therapies that represent revolutionary non-chemotherapy based approaches for treating breast cancer. Her clinical and research interests include various topics in breast cancer including endocrine therapy, novel HER2 therapies, breast cancer vaccines, and other experimental therapeutics.
Blackwell has studied and served as the principal investigator on studies that led to regulatory approval of four cancer agents, including the first biosimilar treatment for cancer in the United States. Due to her leadership, she has received numerous awards, including the Duke University Distinguished Alumni in 2015 and TIME Magazine’s 100 Most Influential People in the World in 2013.
Additionally, Blackwell is a recipient of the Young Investigator Award in breast cancer from the National Cancer Institute Specialized Program of Research Excellence and the Joseph Greenfield Award for Mentorship of Clinical Research.